An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models
- 30 April 2001
- journal article
- research article
- Published by Elsevier in Toxicology Letters
- Vol. 121 (2) , 97-106
- https://doi.org/10.1016/s0378-4274(01)00327-7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Characterization of the Interaction of TZT‐1027, a Potent Antitumor Agent, with TubulinJapanese Journal of Cancer Research, 2000
- Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 DerivativeJapanese Journal of Cancer Research, 1997
- Phase I Clinical and Pharmacokinetic Study of LU103793 (Cemadotin Hydrochloride) as an Intravenous Bolus Injection in Patients with Metastatic Solid TumorsOncology Research and Treatment, 1996
- Peripheral Neuropathy Induced by Intravenous Administration of Vincristine Sulfate in the Rabbit.Toxicologic Pathology, 1995
- Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs.CHEMICAL & PHARMACEUTICAL BULLETIN, 1995
- Etoposide- and BMY-40481-Induced Sensory Neuropathy in MiceToxicologic Pathology, 1994
- The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeuticsPharmacology & Therapeutics, 1991
- General toxicity and peripheral nerve alterations induced by chronic vincristine treatment in the rabbitToxicology and Applied Pharmacology, 1988
- Studies on the pathogenesis of vincristine‐induced neuropathyMuscle & Nerve, 1987
- Axonal transport disturbances in vincristine‐induced peripheral neuropathyAnnals of Neurology, 1977